A
Aaron S. Rosenberg
Researcher at University of California, Davis
Publications - 61
Citations - 840
Aaron S. Rosenberg is an academic researcher from University of California, Davis. The author has contributed to research in topics: Medicine & Population. The author has an hindex of 12, co-authored 44 publications receiving 479 citations. Previous affiliations of Aaron S. Rosenberg include Tufts Medical Center & University of California.
Papers
More filters
Journal ArticleDOI
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial
Shaji Kumar,Susanna Jacobus,Adam D. Cohen,Matthias Weiss,Natalie S. Callander,Avina K. Singh,Terri L. Parker,Alexander R. Menter,Xuezhong Yang,Benjamin M. Parsons,Pankaj Kumar,Prashant Kapoor,Aaron S. Rosenberg,Jeffrey A. Zonder,Edward A. Faber,Sagar Lonial,Kenneth C. Anderson,Paul G. Richardson,Robert Z. Orlowski,Lynne I. Wagner,S. Vincent Rajkumar +20 more
TL;DR: This multicentre, open-label, phase 3, randomised controlled trial aimed to assess whether the KRd regimen is superior to the VRd regimen in the treatment of newly diagnosed multiple myeloma in patients who were not being considered for immediate autologous stem-cell transplantation (ASCT).
Journal ArticleDOI
Targeting MCL-1 in hematologic malignancies: Rationale and progress
Andrew H. Wei,Andrew W. Roberts,Andrew Spencer,Aaron S. Rosenberg,David S. Siegel,Roland B. Walter,Sean Caenepeel,Paul E. Hughes,Zach McIver,Khalid Mezzi,Phuong Khanh Morrow,Anthony S. Stein +11 more
TL;DR: In summary, inhibition of MCL-1 shows potential as a treatment for hematologic malignancies and clinical evaluation of M CL-1 inhibitors is currently underway.
Journal ArticleDOI
Second Primary Malignant Neoplasms and Survival in Adolescent and Young Adult Cancer Survivors.
TL;DR: The adverse impact of SPMs on survival is substantial for AYAs and may partially explain the relative lack of survival improvement in AY as compared with other age groups and inform age-specific prevention, screening, treatment, and survivorship recommendations.
Journal ArticleDOI
Increased incidence of VTE in sickle cell disease patients: risk factors, recurrence and impact on mortality
TL;DR: The high incidence of recurrent VTE in patients with severe SCD suggests that extended anticoagulation may be indicated and was associated with increased mortality in this population‐based study.
Journal ArticleDOI
Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era.
Li Tao,Christina A. Clarke,Christina A. Clarke,Aaron S. Rosenberg,Ranjana H. Advani,Brian A. Jonas,Christopher R. Flowers,Theresa H.M. Keegan +7 more
TL;DR: Insight is provided into the changing pattern of S PM occurrence after the introduction of rituximab, which may elucidate the aetiology of SPMs and should guide future cancer surveillance efforts among DLBCL patients.